Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects.

Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 0374672 Publication Model: Print Cited Medium: Print ISSN: 0019-2805 (Print) Linking ISSN: 00192805 NLM ISO Abbreviation: Immunology Subsets: MEDLINE

Original Publication: Oxford : Blackwell Scientific Publications

Complement Pathway, Classical*; CD59 Antigens/*metabolism ; Diabetes Mellitus, Type 1/*immunology ; Erythrocytes/*immunology; Aged ; Female ; Hemolysis ; Humans ; Male ; Middle Aged

Type 1 diabetes is associated with anaemia. Although the underlying mechanisms remain unclear, the accompanying reticulocytosis implies that erythrocyte lifespan in the circulation is shortened. Among the factors that permit prolonged survival of erythrocytes are the membrane complement regulators. In conditions such as paroxysmal nocturnal haemoglobinuria, where erythrocyte expression of these regulators is reduced, erythrocyte survival is compromised and anaemia follows. Recent in vitro evidence indicates that one of the key membrane complement regulators, CD59, is inactivated by glycation in the presence of high concentrations of glucose or other glycating sugars. To ascertain whether glycation-induced inactivation of CD59 occurrs in vivo we examined CD59 surface expression and function on erythrocytes from a cohort with poorly controlled type 1 diabetes (hyperglycaemic) and from matched normoglycaemic controls. Although expression of CD59, assessed using polyclonal anti-CD59 antiserum, was similar in the two groups, erythrocytes from hyperglycaemic individuals were more susceptible to lysis by complement, entirely as a result of the loss of functional CD59. These data implicate glycation-induced inactivation of CD59 as a factor contributing to anaemia in type 1 diabetes.

JPEN J Parenter Enteral Nutr. 1991 Jan-Feb;15(1):60-4. (PMID: 2008035)
Biochem J. 1991 Mar 1;274 ( Pt 2):473-80. (PMID: 2006911)
Diabetologia. 1980 Nov;19(5):486. (PMID: 7004971)
Diabetes Care. 1992 Dec;15(12):1835-43. (PMID: 1464241)
Scand J Clin Lab Invest. 1990 Nov;50(7):739-46. (PMID: 2149885)
N Engl J Med. 1990 Oct 25;323(17):1184-9. (PMID: 1699124)
J Exp Med. 1997 Feb 3;185(3):507-16. (PMID: 9053451)
J Exp Med. 1997 Feb 17;185(4):745-53. (PMID: 9034152)
Clin Exp Immunol. 1997 Feb;107(2):364-71. (PMID: 9030877)
Immunology. 1990 Sep;71(1):1-9. (PMID: 1698710)
Blood. 1995 Nov 1;86(9):3277-86. (PMID: 7579428)
Atherosclerosis. 1995 Aug;116(2):235-40. (PMID: 7575778)
Lab Invest. 1996 Sep;75(3):325-38. (PMID: 8804356)
Blood. 1989 Jul;74(1):437-41. (PMID: 2473800)
Clin Chem. 1987 Dec;33(12):2220-4. (PMID: 3690840)
J Biol Chem. 1983 Aug 10;258(15):9406-12. (PMID: 6409904)
Transfusion. 1983 Jan-Feb;23(1):11-4. (PMID: 6829053)
Diabet Med. 1999 Oct;16(10):813-9. (PMID: 10547207)
BMJ. 2000 Apr 15;320(7241):1062-6. (PMID: 10764371)
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5450-5. (PMID: 10805801)
Aust N Z J Med. 2000 Jun;30(3):351-9. (PMID: 10914753)
BMJ. 2000 Aug 12;321(7258):405-12. (PMID: 10938048)
BMJ. 2000 Aug 12;321(7258):412-9. (PMID: 10938049)
Diabetologia. 2000 Aug;43(8):1039-47. (PMID: 10990082)
N Engl J Med. 2001 Apr 5;344(14):1058-66. (PMID: 11287977)
Blood. 2001 Jul 15;98(2):442-9. (PMID: 11435315)
Circulation. 2002 Feb 19;105(7):816-22. (PMID: 11854121)
Diabetologia. 1980 Mar;18(3):205-7. (PMID: 7372025)
Eur J Clin Chem Clin Biochem. 1993 Nov;31(11):749-52. (PMID: 8305618)
Diabetologia. 1982 Mar;22(3):223. (PMID: 7075922)

0 (CD59 Antigens)

Date Created: 20050126 Date Completed: 20050309 Latest Revision: 20181113

20250114

PMC1782070

10.1111/j.1365-2567.2004.02086.x

15667573